434 related articles for article (PubMed ID: 30131383)
21. DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer.
Palacio S; McMurry HS; Ali R; Donenberg T; Silva-Smith R; Wideroff G; Sussman DA; Rocha Lima CMS; Hosein PJ
J Gastrointest Oncol; 2019 Dec; 10(6):1133-1139. PubMed ID: 31949930
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer.
Wang ZQ; Zhang F; Deng T; Zhang L; Feng F; Wang FH; Wang W; Wang DS; Luo HY; Xu RH; Ba Y; Li YH
Cancer Commun (Lond); 2019 May; 39(1):26. PubMed ID: 31068222
[TBL] [Abstract][Full Text] [Related]
23. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
Blair AB; Groot VP; Gemenetzis G; Wei J; Cameron JL; Weiss MJ; Goggins M; Wolfgang CL; Yu J; He J
J Am Coll Surg; 2018 Apr; 226(4):630-637.e1. PubMed ID: 29309945
[TBL] [Abstract][Full Text] [Related]
24. Response in
Campoverde LE; Batalini F; Bulushi Y; Bullock A
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35487638
[TBL] [Abstract][Full Text] [Related]
25. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.
Pishvaian MJ; Wang H; He AR; Hwang JJ; Smaglo BG; Kim SS; Weinberg BA; Weiner LM; Marshall JL; Brody JR
Clin Cancer Res; 2020 Oct; 26(19):5092-5101. PubMed ID: 32669374
[TBL] [Abstract][Full Text] [Related]
26. Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?
Wang M; Zhu P; Chen Z; Yang L
Anticancer Drugs; 2022 Jan; 33(1):e686-e691. PubMed ID: 34459461
[TBL] [Abstract][Full Text] [Related]
27. Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma.
Laurent-Badr Q; Barbe C; Brugel M; Hautefeuille V; Volet J; Grelet S; Desot E; Botsen D; Deguelte S; Pitta A; Abdelli N; Brasseur M; De Mestier L; Neuzillet C; Bouché O
Dig Liver Dis; 2020 Jun; 52(6):658-667. PubMed ID: 32362489
[TBL] [Abstract][Full Text] [Related]
28. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
Chevalier H; Vienot A; Lièvre A; Edeline J; El Hajbi F; Peugniez C; Vernerey D; Meurisse A; Hammel P; Neuzillet C; Borg C; Turpin A
Oncologist; 2020 Nov; 25(11):e1701-e1710. PubMed ID: 32886823
[TBL] [Abstract][Full Text] [Related]
29. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
[TBL] [Abstract][Full Text] [Related]
30. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
Park H; Jin RU; Wang-Gillam A; Suresh R; Rigden C; Amin M; Tan BR; Pedersen KS; Lim KH; Trikalinos NA; Acharya A; Copsey ML; Navo KA; Morton AE; Gao F; Lockhart AC
JAMA Oncol; 2020 Aug; 6(8):1231-1240. PubMed ID: 32469386
[TBL] [Abstract][Full Text] [Related]
31. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma.
Hu H; Zhu Y; Pu N; Burkhart RA; Burns W; Laheru D; Zheng L; He J; Goggins MG; Yu J
J Am Coll Surg; 2020 Nov; 231(5):527-535.e14. PubMed ID: 32659497
[TBL] [Abstract][Full Text] [Related]
32. Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison.
van Veldhuisen E; Vroomen LG; Ruarus AH; Derksen TC; Busch OR; de Jong MC; Kazemier G; Puijk RS; Sorgedrager NS; Vogel JA; Scheffer HJ; van Lienden KP; Wilmink JW; Besselink MG; Meijerink MR
J Vasc Interv Radiol; 2020 Oct; 31(10):1600-1608. PubMed ID: 32861569
[TBL] [Abstract][Full Text] [Related]
33. FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.
Bachet JB; Lucidarme O; Levache CB; Barbier E; Raoul JL; Lecomte T; Desauw C; Brocard F; Pernot S; Breysacher G; Lagasse JP; Di Fiore F; Etienne PL; Dupuis OJM; Aleba A; Lepage C; Taieb J;
Eur J Cancer; 2018 Nov; 104():108-116. PubMed ID: 30343254
[TBL] [Abstract][Full Text] [Related]
34. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial.
Dahan L; Williet N; Le Malicot K; Phelip JM; Desrame J; Bouché O; Petorin C; Malka D; Rebischung C; Aparicio T; Lecaille C; Rinaldi Y; Turpin A; Bignon AL; Bachet JB; Seitz JF; Lepage C; François E;
J Clin Oncol; 2021 Oct; 39(29):3242-3250. PubMed ID: 34288696
[TBL] [Abstract][Full Text] [Related]
35. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.
Ramanathan RK; McDonough SL; Philip PA; Hingorani SR; Lacy J; Kortmansky JS; Thumar J; Chiorean EG; Shields AF; Behl D; Mehan PT; Gaur R; Seery T; Guthrie KA; Hochster HS
J Clin Oncol; 2019 May; 37(13):1062-1069. PubMed ID: 30817250
[TBL] [Abstract][Full Text] [Related]
36. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
Kondoh C; Kadowaki S; Komori A; Narita Y; Taniguchi H; Ura T; Ando M; Muro K
Gastric Cancer; 2018 Nov; 21(6):1050-1057. PubMed ID: 29658055
[TBL] [Abstract][Full Text] [Related]
37. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.
Cecchini M; Miccio JA; Pahade J; Lacy J; Salem RR; Johnson SB; Blakaj A; Stein S; Kortmansky JS; Johung KL
Pancreas; 2020 Aug; 49(7):904-911. PubMed ID: 32658074
[TBL] [Abstract][Full Text] [Related]
38. Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma.
Ecker BL; Court CM; Janssen QP; Tao AJ; D'Angelica MI; Drebin JA; Gonen M; O'Reilly EM; Jarnagin WR; Wei AC;
J Am Coll Surg; 2022 Aug; 235(2):342-349. PubMed ID: 35839413
[TBL] [Abstract][Full Text] [Related]
39. Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma.
Yadav S; Kasi PM; Bamlet WR; Ho TP; Polley EC; Hu C; Hart SN; Rabe KG; Boddicker NJ; Gnanaolivu RD; Lee KY; Lindstrom TH; Petersen GM; Couch FJ; McWilliams RR
Clin Cancer Res; 2020 Dec; 26(24):6505-6512. PubMed ID: 33028596
[TBL] [Abstract][Full Text] [Related]
40. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen.
Garnier J; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Giovannini M; Poizat F; Delpero JR; Turrini O
Eur J Surg Oncol; 2020 Aug; 46(8):1510-1515. PubMed ID: 32146053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
